Amicus Therapeutics Inc (FOLD)vsVertex Pharmaceuticals Inc (VRTX)
FOLD
Amicus Therapeutics Inc
$14.49
0.00%
HEALTHCARE · Cap: $4.55B
VRTX
Vertex Pharmaceuticals Inc
$496.07
+2.49%
HEALTHCARE · Cap: $121.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1885% more annual revenue ($12.59B vs $634.21M). VRTX leads profitability with a 35.0% profit margin vs -4.3%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
FOLD
Avoid30
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FOLD.
Margin of Safety
+50.1%
Fair Value
$971.64
Current Price
$496.07
$475.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.7% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Areas to Watch
Trading at 16.5x book value
Elevated debt levels
Weak financial health signals
ROE of -9.9% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FOLD
The strongest argument for FOLD centers on Revenue Growth. Revenue growth of 23.7% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : FOLD
The primary concerns for FOLD are Price/Book, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
FOLD profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
FOLD carries more volatility with a beta of 0.48 — expect wider price swings.
FOLD is growing revenue faster at 23.7% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 30/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amicus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?